A Double-Blind, Randomized Study of Olanzapine and Olanzapine/Fluoxetine Combination for Major Depression With Psychotic Features

  title={A Double-Blind, Randomized Study of Olanzapine and Olanzapine/Fluoxetine Combination for Major Depression With Psychotic Features},
  author={Anthony J. Rothschild and Douglas J. Williamson and Mauricio Tohen and Alan Schatzberg and Scott W. Andersen and Luann E Van Campen and Todd M. Sanger and Gary D. Tollefson},
  journal={Journal of Clinical Psychopharmacology},
Abstract: The purpose of this study was to compare the efficacy and safety of olanzapine (OLZ) monotherapy and an olanzapine/fluoxetine combination (OFC) with placebo (PLA) for unipolar major depression with psychotic features. Under a single protocol, two 8-week, double-blind trials were conducted at 27 sites. Patients (n = 124 trial 1, n = 125 trial 2) were randomized to 1 of 3 treatment groups: OLZ (5 to 20 mg/d), PLA, or OFC (olanzapine 5 to 20 mg/d + fluoxetine 20 to 80 mg/d). The primary… 

Olanzapine/fluoxetine combination for treatment-resistant depression: a controlled study of SSRI and nortriptyline resistance.

The olanzapine/fluoxetine combination did not differ significantly from the other therapies at endpoint, although it demonstrated a more rapid response that was sustained until the end of treatment.

A double-blind randomized controlled trial of olanzapine plus sertraline vs olanzapine plus placebo for psychotic depression: the study of pharmacotherapy of psychotic depression (STOP-PD).

Combination pharmacotherapy is efficacious for the treatment of MD with psychotic features and future research must determine the benefits vs risks of continuing atypical antipsychotic medications beyond 12 weeks.

A randomized, double‐blind comparison of olanzapine/fluoxetine combination, olanzapine, fluoxetine, and venlafaxine in treatment‐resistant depression

The OFC had a safety profile comparable to its component monotherapies, showed a rapid onset of antidepressant effect, and was effective in this TRD sample.

Olanzapine in the treatment of depression with psychotic features: A prospective open-label study

Olanzapine is effective and tolerable in combination with an antidepressant in an MDDp inpatient sample, and concur with data supporting good efficacy in negative and depressive symptoms of patients with schizophrenic and schizoaffective diseases.

Quetiapine in combination with citalopram in patients with unipolar psychotic depression

Olanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility

  • S. DoddM. Berk
  • Psychology, Medicine
    Expert review of neurotherapeutics
  • 2008
Treatment using olanzapine/fluoxetine combination (OFC) is one of many options and has been associated with some side effects, including weight gain and the metabolic syndrome, somnolence, dry mouth, increased appetite and headache.

Aripiprazole versus haloperidol treatment in early-stage schizophrenia.

Weight gain during olanzapine treatment for psychotic depression: effects of dose and age

Age was observed to have a significant negative association with weight gain (P=0.01), even after controlling for differences in cumulative dose and baseline body mass index, and cumulative olanzapine dose was also significantly associated with weightgain.

Examen critique Augmentation of olanzapine in treatment-resistant schizophrenia

The combination of olanzapine with antidopaminergic atypical antipsychotic agents seems to follow a neurobiological rationale, and the augmentation trials with non-antipsychotic Agents were successful and showed that randomized and placebo-controlled trials are feasible.



Efficacy of olanzapine in acute bipolar mania: a double-blind, placebo-controlled study. The Olanzipine HGGW Study Group.

Olanzapine demonstrated greater efficacy than placebo in the treatment of acute bipolar mania and was generally well tolerated.

Efficacy of the combination of fluoxetine and perphenazine in the treatment of psychotic depression.

Fluoxetine when used in combination with perphenazine for the treatment of patients with psychotic depression has a response rate similar to the reported rates of response for tricyclic antidepressants, TCA plus antipsychotics, amoxapine, and electroconvulsive therapy.

Olanzapine: an updated review of its use in the management of schizophrenia.

Olanzapine demonstrated superior antipsychotic efficacy compared with haloperidol in the treatment of acute phase schizophrenia, and in thetreatment of some patients with first-episode or treatment-resistant schizophrenia.

Olanzapine versus haloperidol in the treatment of schizoaffective disorder

Olanzapine demonstrated substantial advantages over the conventional antipsychotic haloperidol in the management of schizoaffective disorder.

Venlafaxine versus fluvoxamine in the treatment of delusional depression: a pilot double-blind controlled study.

The results of this pilot double-blind trial show that fluvoxamine is useful in the treatment of delusional depression and suggest that venlafaxine may also be an effective compound in the Treatment of this disorder.

Risperidone versus haloperidol and amitriptyline in the treatment of patients with a combined psychotic and depressive syndrome.

The results of this trial suggest that the therapeutic effect of HAL/AMI is superior to RIS in the total group of patients with combined psychotic and depressive symptoms, but subgroup differences have to be considered.

Management of psychotic, treatment-resistant depression.

  • A. Rothschild
  • Psychology, Medicine
    The Psychiatric clinics of North America
  • 1996

Long‐term treatment of psychotic (delusional) depression with fluvoxamine: an open pilot study

Fluvoxamine might be a promising drug for long-term therapy of delusional depression and further controlled studies are required to confirm this finding.

A novel augmentation strategy for treating resistant major depression.

Olanzapine plus fluoxetine demonstrated superior efficacy for treating resistant depression compared to either agent alone.